Different DR phenotypes in type 2 diabetes show different risks of retinopathy progression. Phenotype C is associated with increased HbA1c values and presents a higher risk of a 2-or-more-step worsening of the ETDRS severity score (Acta Diabetologica)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants (The Lancet Diabetes & Endocrinology)
2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial
These data show for the first time, to our knowledge, reversibility of the abnormal pancreas morphology of type 2 diabetes by weight loss-induced remission (The Lancet Diabetes & Endocrinology)
Chronic kidney disease and undiagnosed atrial fibrillation in individuals with diabetes
Among individuals with diabetes, CKD significantly increases the risk of incident AF. Identification of AF prior to clinical symptoms through active ECG screening could help to improve the clinical outcomes in individuals with CKD and diabetes (Cardiovascular Diabetology)
Effects of SGL2 inhibitors on liver parameters and steatosis: a meta‐analysis of randomized clinical trials
Treatment with SGLT2 inhibitors improves liver structure and function in patients with type 2 diabetes. This meta‐analysis suggests that SGLT2 inhibitors are a promising pharmacological approach to NAFLD (Diabetes/Metabolism Research and Reviews)
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19
In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment (Diabetes Care)
Next steps in the identification of gene targets for type 1 diabetes
The purpose of this review is to provide a view of the future of genomics and other omics approaches in defining the genetic contribution to all stages of risk of type 1 diabetes and the functional impact and clinical implementations of the associated variants (Diabetologia)
Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects
Soluble EGFR, a hepatokine, is correlated with insulin resistance in the liver, while adipsin, an adipokine, is associated with adipose insulin resistance (Diabetology & Metabolic Syndrome)
Alterations of Gut Microbiota in Type 2 Diabetes Individuals and the Confounding Effect of Antidiabetic Agents
The findings of this study have added a novel understanding about the pathogenesis of the disease and the mechanisms underlying antidiabetic therapy, which are of potential interest for therapeutic lines and further studies (Journal of Diabetes Research)
The Digital/Virtual Diabetes Clinic: The Future Is Now
Recommendations from an International Panel on Diabetes Digital Technologies Introduction (Diabetes Technology and Therapeutics)
Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study
Real-life population-based data suggest a positive effect of metformin on depression rates. This evidence should be used in guiding prescriptions for patients with type 2 diabetes who are at risk for developing depression, including those with prior depression or anxiety and patients with a family history of depression (Diabetes Care)
Modeling Carbohydrate Counting Error in Type 1 Diabetes Management
The most important predictors of CHO counting errors are CHO and meal type. The mathematical models proposed improve the description of patients’ behavior in the T1D patient decision simulator (Diabetes Technology and Therapeutics)
Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial
Eighteen months of metformin treatment in combination with insulin compared with insulin alone increased early drop in OBP indicating an adverse effect of metformin on CAN independent of vitamin B12, MMA HbA1c (Cardiovascular Diabetology)
Dapagliflozin in Patients with Chronic Kidney Disease
Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo (NEJM)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events (NEJM)
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
Once-weekly treatment with insulin icodec had glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes (NEJM)
Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial
The increased mortality observed in the intensive glycemic control arm in the ACCORD trial is not likely to be explained by QT prolongation leading to lethal ventricular arrhythmias (Diabetes)
Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel
General screening for LADA in newly diagnosed non–insulin-requiring diabetes and, importantly, that large randomized clinical trials are warranted (Diabetes Care)
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
A once-weekly GLP-1RA was able to substitute for prandial insulin in 54% of people, substantially reducing the number of prandial insulin injections; glycemic control improved, with the added benefits of weight loss and less hypoglycemia in the GLP-1RA arm (Diabetes Care)
Multimorbidity, glycaemic variability and time in target range in people with type 2 diabetes: a baseline analysis of the GP-OSMOTIC trial
While multimorbidity was common in this T2D cohort, it was not associ (Diabetes Research and Clinical Practice)ated with HbA1c, CV or TIR. Future studies should explore factors other than glycaemia that contribute to the increased mortality observed in those with multimorbidity and T2D
Glycosmedia is also available as an App: